Connect with us

Health

Critical Medicines Act: Parliament ambition versus Council revision

SHARE:

Published

1 month ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The EU’s Critical Medicines Act (CMA) is becoming the latest battleground between the European Parliament and the Council, as lawmakers clash over how ambitious Europe should be.The European Parliament’s Public Health Committee (SANT) presented the feedback on Tomislav Sokol’s (EPP, Croatia) report on critical medicines today (6 November). In total the SANT committee tabled 1,313 amendments, with additional amendments from the Environment Committee (ENVI) - 119, Research and Industry Committee (ITRA) - 414, and the Internal Market Committee (IMCO) - 221.

Sokol said that there were six scheduled technical meetings in the coming weeks and that he still hoped that it would be possible to have a vote on 2 December.

Some MEPs want a broader definition of medicinal products of common interest, Sokol wants to include orphan medicines and novel antimicrobials. But German MEP Tiemo Wölken, whose views were presented by fellow S&D member Nikos Papandreou, said that these medicines would probably be...

Share this article:

Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending